This was the request that came out of the generics group when they came. They spoke to us about the concerns they have. The pharmaceutical industry in Canada is highly litigious, and a lot of case law exists. That language could be impacted, going back to case law that already exists, so there is a bit of a change here with the preamble in order to reinstate the language of the Patent Act.
I want to be clear that the amendments here, and even this proposal, are not required by CETA. This is one of the pieces where we heard from the generics group that they saw, inside of the changes to the Patent Act, that we are going above and beyond the requirements of CETA.
I'd actually ask Mr. Verheul if he could speak to that, because this was something we heard after his presentation to us. We heard from the generics group that pieces of the legislation go above and beyond what is necessary for enforcement of CETA.
I wonder if you could speak to that. Perhaps you could speak to this particular clause and to whether we could go back to the reinstatement of the language of the Patent Act.